Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into...

Area of Science:

• Oncology
• Nephrology
• Pharmacology

Background:

• Kidney dysfunction significantly impacts anticancer drug efficacy and toxicity.
• Existing guidelines for chemotherapy dosing in renal impairment vary and may not reflect current evidence.
• The International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) was developed to address these limitations.

Purpose of the Study:

• To provide evidence-based, consensus recommendations for anticancer drug dosing in patients with kidney dysfunction.
• To compare ADDIKD recommendations with existing guidance for commonly used anticancer agents.
• To translate complex recommendations into practical clinical guidance.

Main Methods:

• Development of consensus recommendations based on systematic evidence review and expert clinical experience.
• Comparative analysis of ADDIKD dosing for methotrexate, cisplatin, carboplatin, and nivolumab against current standards.
• Distillation of recommendations into actionable practice points for specific agents.

Main Results:

• ADDIKD Part 2 offers specific dosing recommendations for anticancer drugs in kidney dysfunction.
• Significant differences were observed between ADDIKD and existing guidance for methotrexate, cisplatin, carboplatin, and nivolumab.
• Practical guidance was developed for methotrexate and cisplatin dosing.

Conclusions:

• The ADDIKD guideline represents a significant advancement in managing chemotherapy in renal impairment.
• Successful adoption requires stakeholder endorsement, clinician advocacy, and integration into clinical workflows and systems.
• Implementation is crucial for optimizing cancer treatment outcomes in patients with kidney disease.